Chest pain patients (N = 199) consecutively referred to cardiology outpatient clinics were reassessed after nine years by cardiological and psychiatric (SCID I) examinations. Of patients with nonfearful panic disorder (NFPD) (N = 17) at baseline, none fulfilled criteria for NFPD at follow-up, but 18% had panic disorder with fear (PD). The outcome of patients with NFPD and PD (N=59) at baseline did not differ significantly with respect to psychiatric comorbidity, chest pain (SF-MPQ), health care utilization, and health-related quality of life (SF-36). NFPD should be considered a subgroup of PD, which will have a significant impact on the long-term outcome of chest pain patients.
INTRODUCTION
Nonfearful panic disorder (NFPD) is a type of panic disorder (PD) that was first described by Beitman and colleagues in 1987 among cardiology patients who had panic attacks without the experience of fear. 1 These patients met the DSM III-R criteria for PD by reporting attacks of intense discomfort and at least four of the twelve remaining symptoms on the screening checklist, but they did not report subjective free floating anxiety or fear of dying, fear of 'going crazy', or doing something uncontrolled (Table 1) .
To the best of our knowledge, only four previous studies in cardiology and emergency department settings have estimated the prevalence of NFPD and found that 22-44% of PD patients fulfilled the criteria for NFPD. [1] [2] [3] [4] However, the concept of NFPD is somewhat controversial and it remains equivocal whether NFPD is a subgroup of PD or whether it is a distinct diagnostic entity. 5 Questions have also been raised as to whether NFPD may be better classified as a somatoform disorder, or whether NFPD patients have an undetected medical disorder that is wrongly identified as NFPD. 3, 4 Previous studies have concluded that it is reasonable to regard NFPD as a variety of PD rather than a distinct diagnostic entity, because no significant differences have been found between PD and NFPD patients in terms of demographic characteristics, 1, 3, 4 frequency of panic attacks (except the cognitive symptoms of panic attacks), 3 health-related quality of life, 4 prevalence of PD among first-degree relatives, 6 response to treatment with anxiolytic medication (imipramine or lorazepam), 7 and response to lactate infusions in neurological patients with PD and NFPD. 7 However, some studies have reported lower prevalence of comorbid psychiatric disorders and lower scores on self-reported anxiety and panicagoraphobia symptomatology in NFPD patients. 3, 4 Longitudinal studies are clinically important because they provide knowledge of the long-term outcome of diseases; however, we are aware of only one previous study exploring the course of NFPD. Fleet and colleagues conducted a two-year follow-up study that supported the notion that NFPD is a subgroup of PD, as over the two-year period, both groups had either not improved or worsened in self-report measures of anxiety, panic, and agoraphobia. There were no significant differences between the groups in the number of chest pain episodes, emergency department visits, hospitalizations, and perceived health status at follow-up. 3 Nevertheless, this study suffers from methodological limitations such as lack of diagnostic psychiatric assessments at follow-up, no second cardiological evaluation, and absence of assessment of health-related quality of life, which is considered an important target for treatment. The NFPD patients may have developed fear and thus fulfilled the criteria for PD at follow-up, or they may have developed heart disease or other somatic disorders, which could explain their panic-like symptoms and poor prognosis.
To the best of our knowledge, this is the first long-term follow-up study of NFPD.
It was conducted to extend the knowledge of both the concept and clinical outcome of NFPD by rediagnosing the patients nine years after initial examination and comparing the outcome of PD patients with and without fear. It is, therefore, both an important supplement to the validation of the concept of NFPD, and a source of new knowledge regarding the long-term course of NFPD. From outcome studies of PD in psychiatric settings, we know that PD often has a chronic course with serious implications regarding functional and social disability 8 and quality of life. 8, 9 If the course of NFPD is similar to that of PD, it would support the concept of NFPD as a subtype of PD and emphasize the need to recognize this group of patients in order to provide treatment.
We have previously published a study of 199 patients consecutively referred to cardiology outpatient clinics because of chest pain, 4 in which 17 of the 76 patients (22.4%) suffering from PD met the criteria for NFPD. We now present the nine-year follow-up status of this population to (i) estimate the proportion of patients who fulfill the criteria for NFPD and PD at follow-up, and (ii) compare the long-term outcome of the patients with NFPD, PD, and NoPD at baseline. We do this with regard to: a) comorbid psychiatric disorders; b) self-reported anxiety, agoraphobia, somatization, depression, and chest pain; c) presence of somatic disorders; d) health-related quality of life; and e) health care utilization and use of medication.
We hypothesize that the outcome of the NFPD patients will not differ significantly from the outcome of the PD patients and that they will both have a worse outcome than the NoPD patients.
METHODS

Ethics
The study was conducted in accordance with the revised Declaration of Helsinki.
The research protocol was accepted by the Regional Ethics Committee in November 1994. At the time of the baseline and follow-up investigations, all participants signed informed consent forms.
Subjects
Baseline. The baseline participants in the study were 199 patients with no previously documented heart disease who were referred for investigation of chest pain to one of four cardiology outpatient clinics in Oslo, Norway, from December 1994 to November 1996. At the first examination, 32 patients (16%) were diagnosed as suffering from coronary artery disease (CAD) and 167 were diagnosed as having noncardiac chest pain. Seventy-six patients (38%) suffered from PD at initial examination, 17 of which (22.4%) fulfilled the criteria for NFPD. At baseline, no statistically significant difference in gender was found among the PD (patients with NFPD excluded), NFPD, and NoPD patients. Women constituted 58%, 65%, and 43% of the groups, respectively. Patients with PD or NFPD did not differ significantly in age (mean ± SD: 48.1 ± 9.2 vs 49.4 ± 12.9 years, respectively), years of education, or income. Compared to the patients with NoPD, both groups were younger (age of NoPD patients = 52.7 ± 8.8 years), had fewer years of education and lower income. A more detailed description of the study population has been published elsewhere. 4 Follow-up. Between eight and ten years after the baseline study (mean = 8.6 years, range 8.1-9.9 years), patients were asked to participate in a follow-up study. Fourteen patients had died during the follow-up period (four of the PD and two of the NFPD patients) and one patient had suffered a major stroke and was unable to participate. Of the 184 eligible patients, 150 participated in the follow-up study (82%). Of the 34 nonparticipants, seven had left the country, 12 could not be located, and 12 patients did not participate for the following reasons: study not relevant to their condition at Of the 150 participating patients, 12 attended the psychiatric, but not the cardiological evaluation session, which was scheduled to take place about a week after the psychiatric evaluation session. The reasons for their absence are unknown.
They were still considered participants because information about their previous cardiac disorders could be obtained from their medical records.
Assessment of sampling bias. There were no significant differences between the 150 participants and the 34 nonparticipants regarding sex, age, years of education, or income at baseline. The participants also did not differ significantly from nonparticipants in the prevalence of CAD (12% vs 17%, respectively), PD (29.3% vs 30.6%, respectively), NFPD (7.3% vs 12.2%, respectively), or any of the outcome measures at baseline. In order to ensure that the evaluations were blinded, the person who performed the psychiatric interview did not know the result of the previous psychiatric evaluation or previous or current cardiac examinations; likewise, the cardiologists were unaware of the psychiatric evaluation results.
The number of deaths was obtained from the National Death Registry.
Study Groups
The long-term outcome of three groups was compared: patients with panic disorder (PD; N = 44), patients with nonfearful panic disorder (NFPD; N = 11), and patients without panic disorder (NoPD; N = 95) at baseline. Patients were diagnosed with PD if they met the criteria for panic disorder when using the Structured Clinical Interview for DSM IV (SCID).
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The patients were diagnosed with NFPD if they reported having recurrent, unexpected attacks of intense discomfort without reporting fear of dying, 'going crazy', or losing control, but at least four of the remaining symptoms of a panic attack according to the criteria described by Beitman et al. 1 and adjusted to DSM IV ( Table 1 ). The NoPD patients met neither the criteria for PD nor NFPD. 
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Cardiological assessments and registration of somatic disorders. Follow-up evaluations of the study patients were conducted by four cardiologists, one of whom also took part in the baseline study. A cardiological assessment form was completed by the cardiologist for each patient. The form recorded data on the patients' previous or prevailing medical diseases and current medication. In all patients, a standard bicycle ergometer test was performed at baseline and follow-up according to the procedure described by Nordenfelt et al.
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If inconclusive, the test was classified as such, and the patient was referred for further tests, such as thallium scintigraphy or coronary angiography. A cardiologist not participating in the cardiological assessment evaluated and approved all cardiological diagnoses before the final analyses. The classification criteria and procedure for this test are reported in more detail elsewhere.
Statistical Analyses
Comparisons between the PD, NFPD, and NoPD patients were performed using the chi-squared test for dichotomous variables. When an overall difference was found with p < 0.10, we continued with between-group analyses. The independent Student's t test was used for normally distributed continuous variables and the Mann-Whitney U test was used for continuous variables without normal distributions. Distributions were visualized using histograms. All tests were two tailed. Paired-sample t tests were used to estimate change in scores of continuous variables from baseline to follow-up for each of the three study groups. A significance level of 5% was applied. Agreement between interviewers on psychiatric diagnoses was assessed using the kappa coefficient. The SPSS/PC 12.0 statistical package was used for all data analyses. Due to missing data, N may differ for some of the variables.
RESULTS
Prevalence of Panic Disorder and Nonfearful Panic Disorder at Follow-up
The results are shown in Table 2 . Of the patients with current PD at baseline, 27% still suffered from current PD at follow-up while 34% reported a history of PD symptoms. Of the patients with NFPD at baseline, 18% had current PD at follow-up, and 45% reported a history of PD symptoms. No patients fulfilled the criteria for current or historical NFPD at follow-up.
Comparison of Patient Groups
Comorbid axis I disorders at follow-up. The results are shown in Table 3 . There was no significant difference in the prevalence of agoraphobia and anxiety disorders between the study groups. NFPD patients had a significantly higher prevalence of any somatoform disorder compared to NoPD patients. The prevalence of current major depression was significantly higher among PD than NoPD patients and there was a nonsignificant trend (p = 0.051) towards a higher prevalence of history of major depression among the NFPD compared to NoPD patients. There was no significant difference in prevalence of any specific psychiatric disorder between the PD and NFPD patients; however, while 76.3% of the PD patients had any comorbid psychiatric disorder, prevalence in NFPD patients was 54.5% (p = 0.089).
Self-reported anxiety, depression, and somatization at follow-up. Table 4 shows the patients' self-report measures of anxiety, depression, and somatization.
On the SCL-90 anxiety subscale and Agoraphobic Cognitions Questionnaire, PD patients scored significantly higher at follow-up than both NFPD and NoPD patients, and there was no significant difference between the two latter groups. Both PD and NFPD patients had improved from baseline as they had significantly lower SCL-90
anxiety scores at follow-up.
On the SCL-90 somatization subscale, the PD patients scored significantly higher than NoPD patients; otherwise, there was no significant difference between the study groups. All three groups had lower scores at follow-up compared to baseline, but the change was statistically significant for the NFPD and NoPD patients only.
On the SCL-90 depression subscale the PD patients also scored significantly higher than the two other groups at follow-up, while there was no significant difference between the NFPD and NoPD patients. All groups had experienced a small, but nonsignificant improvement from baseline to follow-up.
Chest pain at follow-up. Chest pain in the last month was reported by 65.9% of PD patients, 54.5% of NFPD patients, and 53.7% of NoPD patients, resulting in no significant differences between groups (p = 0.392). Of the 86 patients who had experienced chest pain in the preceding month, PD patients reported significantly more intense pain than the NoPD patients, while the level of pain in the NFPD patients was between the two other groups for all MPQ scales (Table 4) . Regarding the total pain intensity, as measured by a visual analogue scale, NFPD patients had the highest score, although this was not statistically significant from the other groups.
Somatic disorders at follow-up. As seen in Table 5 , PD patients reported a significantly higher prevalence of dyspepsia and peptic ulcer than the NoPD patients, while NFPD patients reported a significantly higher prevalence of peptic ulcer and hypothyreosis than NoPD patients. There was no significant difference in prevalence of somatic disorders between PD and NFPD patients, although the mean number of somatic disorders was slightly higher in the PD group.
Health-related quality of life at follow-up. The quality of life results are presented in Table 6 . PD patients scored significantly lower than NoPD patients (a higher score indicates better health) on all subscales of the SF-36 at follow-up. The scores of the NFPD patients did not differ significantly from those of PD patients, and although the NFPD patients scored lower than the NoPD patients on seven of eight subscales, the differences reached statistical significance for the physical functioning, body pain, and general health subscales only. There was no significant change in SF-36 scores for any of the groups from baseline to follow-up.
Health care utilization last year. A greater proportion of PD and NFPD patients reported seeking medical help for chest pain symptoms (25% and 27% vs 15%; p = 0.264) and for other symptoms (84% and 91% vs 77%; p = 0.463) than patients without PD. These differences, however, did not reach statistical significance.
Although not statistically significant, a greater proportion of the NFPD patients had 
DISCUSSION
The main finding of this study was that while 17 of 76 PD patients met the criteria for NFPD at baseline, none were diagnosed with NFPD nine years later; also, of the 11 NFPD patients who participated in the follow-up interview, more than 60% reported either current PD or a history of PD with fear. Interestingly, 39% of the PD and 36% of the NFPD patients did not fulfill the criteria for any panic disorder at follow-up. We believe this may be explained by the instability of recall, as has previously been reported in patients with somatization disorder 19 and depression. 20 These findings suggest that a majority of the NFPD patients have experienced both fearful and nonfearful panic episodes during the course of their illness. They support the study of Rachman and colleagues 21 that found that, for several panic trials, patients could be divided into three groups: one group reporting exclusively panic attacks with fear; one group reporting exclusively panic attacks without fear; and one group reporting both fearful and nonfearful panic attacks. The participants in our study were diagnosed as having either panic attacks with or without fear, exclusively, based on the last month of attacks; this categorization assumes that this period was representative, although it may not have been. A second evaluation of the NFPD patients may have revealed more anxiety in conjunction with panic attacks than was found in the first examination.
One must also consider whether NFPD patients really did have panic attacks without fear at baseline, or whether they denied their emotional symptoms due to shame or fear of negative stigma associated with psychiatric disorders. Perhaps they were concerned that their physical symptoms would be underestimated and not thoroughly investigated if they admitted cognitive symptoms. This is in line with the finding that only 31% of the patients with PD or NFPD wanted a report with information about panic disorder and treatment options to be sent to their general practitioner after their first psychiatric evaluation. The most commonly stated reason for not experiencing a treatment need was a primary need for clarification of cardiovascular illness.
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The results of the psychiatric diagnostic reevaluation confirm the notion of NFPD as a subgroup of PD rather than a distinct diagnostic entity. Furthermore, as there was no significant difference between the PD and NFPD patients regarding the prevalence of any cardiological or other somatic disease, it seems unlikely that an undetected medical disorder was the cause of symptoms in NFPD patients at baseline. In fact, the number of medical disorders was highest among the PD patients. There was no significant difference in the prevalence of somatoform disorders between the PD and NFPD patients, as the prevalence rates were 25% and 37%, respectively. If NFPD were to be better explained by a somatoform disorder, one would expect a greater overlap of the diagnoses. However, the rates of both medical and somatoform disorders were high for both PD and NFPD patients and it is difficult to know with certainty whether the reported medical conditions were actual diseases or somatoform symptoms. Apart from the cardiological investigation, these disorders were not verified by thorough medical examination, but rather recorded by a cardiologist. Thus, the patients may have reported symptoms they perceived as somatic disorders; i.e., breathing problems explained as asthma, or chest pain explained as dyspepsia or peptic ulcer, when the symptoms may not have been of organic origin. A high prevalence of unexplained physical symptoms is common in patients with anxiety disorders, 22 but a high comorbidity between panic disorder and gastrointestinal disorders as well and asthma has also been reported.
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The symptoms caused by these disorders may serve as internal cues that initiate panic attacks in vulnerable persons. 23 Moreover, we hypothesized that the outcome of the PD and NFPD patients would not differ significantly and that both groups would have a worse outcome than the NoPD patients. This hypothesis was only partially confirmed, as the PD patients had significantly higher scores than the NFPD patients regarding the symptoms of panic and agoraphobia, while there was no significant difference between PD and NFPD patients regarding the development of comorbid psychiatric disorders, persistence of chest pain episodes, health care utilization, and self-reported health-related quality of life.
Previous studies have reported a lower prevalence of agoraphobia in NFPD compared to PD patients 3, 4, 24 and a lower prevalence of generalized anxiety disorder in NFPD patients. 3 After nine years, there were no significant differences in prevalence of any comorbid anxiety disorders between the two groups. The rates of generalized anxiety disorder and specific phobia had increased in both groups compared to baseline and the prevalence of agoraphobia had decreased from 46% to 14% in PD patients from baseline to follow-up, most likely because only 27% of them suffered from current panic attacks at follow-up. Although 18% of NFPD patients suffered from current PD with fear at follow-up, an additional 45% reported a history of PD with fear, and there were similar rates of anxiety disorders in PD and NFPD patients.
This did not seem to affect their experience, or at least their report, of typical panic symptoms. Regarding the self-reported symptoms of panic and agoraphobia, both the PD and NFPD patients had improved at follow-up. However, the PD patients still had significantly higher scores than NFPD patients who had scores no different from the NoPD patients both at baseline and follow-up. Antipanic treatment (i.e., serotonin reuptake inhibitors and high-potency benzodiazepines) may have improved these measures, but we did not collect systematic data regarding the treatment that they may have received during the follow-up period because we believed there would be recall difficulties. However, during the last year, 21% of the PD and 9% of NFPD patients had received such medical treatment. Interestingly, this was also the case for 17% of the NoPD patients.
Regarding health-related quality of life, all groups were unchanged from baseline to follow-up and the outcome of the PD and NFPD patients did not differ significantly, while they both had a worse outcome than the NoPD patients. This is an important finding, as improvement in health-related quality of life is one of the targets for treatment of PD. and patients with other chronic disorders. 9 These findings add to the evidence that NFPD patients are particularly distressed by physical impairment and pain and that this distress is unchanged after nine years. This was also reflected in their use of analgesics, which was significantly higher than in the two other groups, as well as a more frequent use of the health care system by NFPD compared with NoPD patients.
The results of this long-term follow-up study suggest that NFPD should be There is little empirical evidence for the effective treatment of NFPD. To the best of our knowledge, there is only one small study that examined the treatment of NFPD patients, where PD and NFPD patients responded similarly to antidepressive therapy. 7 Cognitive therapy may also be effective as it is one of the treatments of choice in panic disorder 31 and it has also been found to be effective in patients with medically unexplained physical symptoms.
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While cognitive therapy of panic disorder is focused on modifying the patients' catastrophic interpretations of bodily sensations, 33 we speculate that this model may be less suitable in NFPD patients who report less cognitive distortions. A model focusing on stress management, activity regulation, emotional awareness, cognitive restructuring, and interpersonal communication, as that developed by Allen et al. 32 for treatment of patients with medically unexplained symptoms, may be more effective in NFPD patients.
Study Strengths and Limitations
The strengths of this study are that we followed the patients for a long period of time and performed psychiatric and cardiological reevaluation after nine years.
However, we did not collect data regularly throughout the follow-up period.
Therefore, we do not know if the findings at the time of follow-up reflect the psychiatric and medical morbidity of the patients throughout the nine-year period.
Another important issue is whether the differences in psychiatric diagnosis from baseline to follow-up are reliable and not caused by different judgment by the interviewers. However, the last author of this article, who performed the baseline interviews, was the one who made a second evaluation of the interviews at follow-up, and the interrater reliability scores were high. Furthermore, no systematic evaluations of medical disorders other than coronary artery disease were conducted; however, that was not considered to be the main aim of this study.
Dealing with a small study group such as the NFPD patients, which consisted of 17 people at baseline and only 11 at follow-up, weakens the statistical power of the study and makes it susceptible to type 2 errors. Differences between the NFPD and PD patients may thus actually be significant although they are statistically not significant based on the current sample. This may be the case when comparing the two groups regarding current major depression and prevalence of any psychiatric disorder.
However, most of our results showed that differences between the NFPD and PD patients were either clearly not significant or clearly significant.
CONCLUSION
This long-term follow-up study of NFPD patients supports the position that NFPD is a subgroup of PD, as the majority of NFPD patients experience panic attacks with fear during the course of their illness. The outcome of NFPD patients is as severe as that of the PD patients regarding health-related quality of life, although the symptom profiles of the two groups differ somewhat. The challenge is to make primary care physicians aware of this subgroup of PD and, further, to educate and motivate the patients to receive psychiatric treatment even if they do not feel psychiatrically ill. 
